

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10825 U.S. PTO
09/680514
10/06/00



In re CIP of Patent Application Serial No.08/765,337 of

YOKOI et al

Atty. Ref.: 249-118

Serial No. to be assigned

Group: 1646

Filed: October 6, 2000

Examiner: Mertz

For: HG-CSF FUSION POLYPEPTIDE HAVING C-MPL
ACTIVITY, DNA CODING FOR SAME AND METHODS
OF TREATING ANEMIA USING SAME(AS AMENDED)

* * * * *

October 6, 2000

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. § 1.55 and in
conformance with the procedures of 37 C.F.R. § 1.98, applicants hereby bring the
following references_[sp2] to the attention of the examiner. These references_[sp3] are listed on
the attached modified PTO Form No. 1449. It is respectfully requested that the
information be expressly considered during the prosecution of this application, and that
the references_[sp4] be made of record therein and appear among the "References Cited" on
any patent to issue therefrom. A copy of the patent, publication or other information
listed on the modified PTO form 1449 is enclosed.

Please return to the undersigned a copy of the attached PTO-1449 with the
examiner's initials in the left column [MPEP § 609] with the next communication.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Arthur R. Crawford

Reg. No. 25,327

ARC:pfc
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100